Over the past decades CRISPR, short for “clustered regularly interspaced short palindromic repeats”, has become somewhat of a household name, holding the promise of directly addressing genetic mutations by effectively removing, silencing, or even fixing them. Yet the original purpose of CRISPR is slightly less cute and cuddly: the evolutionary origin of these DNA sequences is that of a core component of the prokaryotic immune system.
In most medical applications today we only try to use CRISPR to detect sequences and then apply enzymes such as the well-known Cas9 to cut DNA at specific locations in the process of gene-editing. In a recent study (paywalled, bioRxiv pre-print) by Jingkun Zheng et al. in Nature such benign enzymes are dropped for Cas12a2, which turns a detection event into the release of a DNA-destroy enzyme as the molecular equivalent of a guided missile.
The pitched use case here is the detection of cancer-cell specific mutations in the DNA, following which the tumor cells will be instantly shredded from the inside. This could theoretically provide a cure for many cancer types, but should we expect to see this kind of therapy approved any time soon?
Continue reading “How CRISPR Could Mark Mutated Cancer Cells For Termination”








